Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 116 entries
View as:

The Detection of Circulating Tumor Cells (CTCs) in Patients With Breast Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02450357 Org: User:
Start: 06/30/13 End: 12/31/15 Due: 12/31/16

Safety and Efficiency of γδ T Cell Against Non Small Lung Cancer ( Without EGFR Mutation)

Phase: N/A Priority: Normal
NCT ID: NCT02425748 Org: User:
Start: 06/08/17 End: 06/20/19 Due: 06/20/20

The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02450422 Org: User:
Start: 06/30/13 End: 12/31/15 Due: 12/31/16

Combination of Trastuzumab and NK Immunotherapy for Recurrent Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02843126 Org: User:
Start: 07/01/16 End: 07/01/19 Due: 07/01/20

Combination of Cryosurgery and NK Immunotherapy for Advanced Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02843815 Org: User:
Start: 07/01/16 End: 07/01/19 Due: 07/01/20

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA）for Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02523404 Org: User:
Start: 05/31/15 End: 08/31/16 Due: 08/31/17

Combination of Rituximab and NK Immunotherapy for B Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02843061 Org: User:
Start: 07/01/16 End: 07/01/19 Due: 07/01/20

Irreversible Electroporation(IRE) For Unresectable Extremities Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT02430688 Org: User:
Start: 01/01/15 End: 02/01/21 Due: 02/01/22

A Phase I/II Study of Active Immunotherapy With Cancer Stem Cells Vaccine for Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02176746 Org: User:
Start: 06/30/14 End: 05/31/15 Due: 05/31/16

Safety and Efficiency of γδ T Cell Against Hepatocellular Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02425735 Org: User:
Start: 04/30/15 End: 06/30/16 Due: 06/30/17

HepaSphere Interventional Therapy Using Digital Subtraction Angiography（DSA） for Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02447263 Org: User:
Start: 05/31/15 End: 02/29/16 Due: 02/28/17

CAR-T Cell Immunotherapy for EphA2 Positive Malignant Glioma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02575261 Org: User:
Start: 09/30/15 End: 08/15/16 Due: 08/15/17

Percutaneous Irreversible Electroportion in Unresectable Liver Cancer Close to Diaphragmatic Dome

Phase: N/A Priority: Normal
NCT ID: NCT02329106 Org: User:
Start: 12/01/14 End: 01/01/21 Due: 01/01/22

Nano Drug Interventional Therapy Using Digital Subtraction Angiography（DSA） for Lung Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT02449122 Org: User:
Start: 05/31/15 End: 02/29/16 Due: 02/28/17

Bioinformation Therapy for Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03350477 Org: User:
Start: 11/30/17 End: 11/30/18 Due: 11/30/19

Irreversible Electroporation(IRE) For Unresectable Stomach Neoplasms

Phase: N/A Priority: Normal
NCT ID: NCT02430636 Org: User:
Start: 01/01/15 End: 02/01/21 Due: 02/01/22

Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03524274 Org: User:
Start: 04/05/18 End: 08/05/20 Due: 08/05/21

Irreversible Electroporation(IRE) For Unresectable Portal Venous Tumor Emboli

Phase: N/A Priority: Normal
NCT ID: NCT02333773 Org: User:
Start: 01/01/15 End: 01/01/21 Due: 01/01/22

Combination of Irreversible Electroporation and NK Immunotherapy for Recurrent Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03008343 Org: User:
Start: 12/01/16 End: 07/01/19 Due: 07/01/20

The Detection of Circulating Tumor Cells (CTCs) in Patients With Liver Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02416635 Org: User:
Start: 06/30/13 End: 12/31/15 Due: 12/31/16

Safety and Efficiency of γδ T Cell Against Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03183232 Org: User:
Start: 06/15/17 End: 06/15/19 Due: 06/15/20

High-activity Natural Killer Immunotherapy for Small Metastases of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03008499 Org: User:
Start: 12/01/16 End: 09/01/19 Due: 09/01/20

Safety and Efficiency of γδ T Cell Against Liver Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03183219 Org: User:
Start: 06/15/17 End: 06/15/19 Due: 06/15/20

Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02845856 Org: User:
Start: 07/01/16 End: 07/01/19 Due: 07/01/20

Mix Vaccine for Metastatic Kidney Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03357289 Org: User:
Start: 11/30/17 End: 08/30/19 Due: 08/30/20